C4 Therapeutics annual stock-based compensation
2019
2020
2021
2022
2023
2024
2025
C4 Therapeutics Stock-Based Compensation Growth & History (CCCC)
C4 Therapeutics's stock-based compensation was $19.1M for fiscal 2025.
View full C4 Therapeutics company overviewC4 Therapeutics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $19.1M | −$10.6M | −35.61% |
| 2024 | 2024-12-31 | $29.7M | $2.4M | +8.91% |
| 2023 | 2023-12-31 | $27.2M | −$2.8M | −9.27% |
| 2022 | 2022-12-31 | $30.0M | $8.5M | +39.53% |
| 2021 | 2021-12-31 | $21.5M | $18.1M | +526.81% |
| 2020 | 2020-12-31 | $3.4M | $1.8M | +109.01% |
| 2019 | 2019-12-31 | $1.6M | — | — |
C4 Therapeutics quarterly stock-based compensation
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $3.0M | −$2.0M | −39.18% |
| Q1 2026 | 2026-03-31 | $2.7M | −$2.8M | −51.50% |
| Q4 2025 | 2025-12-31 | $4.0M | −$4.2M | −51.34% |
| Q3 2025 | 2025-09-30 | $4.6M | −$4.2M | −47.99% |
| Q2 2025 | 2025-06-30 | $5.0M | −$1.4M | −21.77% |
| Q1 2025 | 2025-03-31 | $5.5M | −$708,000 | −11.39% |
| Q4 2024 | 2024-12-31 | $8.2M | $1.9M | +29.50% |
| Q3 2024 | 2024-09-30 | $8.8M | $631,000 | +7.70% |
| Q2 2024 | 2024-06-30 | $6.4M | −$44,000 | −0.68% |
| Q1 2024 | 2024-03-31 | $6.2M | −$36,000 | −0.58% |
| Q4 2023 | 2023-12-31 | $6.4M | −$560,000 | −8.09% |
| Q3 2023 | 2023-09-30 | $8.2M | $2.2M | +36.42% |
| Q2 2023 | 2023-06-30 | $6.4M | −$1.7M | −21.15% |
| Q1 2023 | 2023-03-31 | $6.3M | −$2.7M | −30.06% |
| Q4 2022 | 2022-12-31 | $6.9M | $566,000 | +8.91% |
| Q3 2022 | 2022-09-30 | $6.0M | −$75,000 | −1.23% |
| Q2 2022 | 2022-06-30 | $8.1M | $2.9M | +55.85% |
| Q1 2022 | 2022-03-31 | $8.9M | $5.1M | +132.46% |
| Q4 2021 | 2021-12-31 | $6.4M | $3.6M | +133.65% |
| Q3 2021 | 2021-09-30 | $6.1M | $5.7M | +1295.87% |
| Q2 2021 | 2021-06-30 | $5.2M | $5.1M | +3147.20% |
| Q1 2021 | 2021-03-31 | $3.8M | $3.7M | +3214.66% |
| Q4 2020 | 2020-12-31 | $2.7M | — | — |
| Q3 2020 | 2020-09-30 | $436,000 | −$191,000 | −30.46% |
| Q2 2020 | 2020-06-30 | $161,000 | — | — |
| Q1 2020 · Mar 31 | 2020-03-31 | $116,000 | — | — |
| Q3 2019 | 2019-09-30 | $627,000 | — | — |
C4 Therapeutics stock-based compensation trends
Over the last five fiscal years, C4 Therapeutics's stock-based compensation increased from $3.4M to $19.1M, a change of $15.7M. The latest reported quarter, Q2 2026, shows $3.0M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review C4 Therapeutics source filings ↗